Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...

As policies from the last two presidential administrations put heightened focus on drug affordability in the United States, a ...

Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

The FDA is codifying its regulations around mobile apps that go along with prescription drugs, offering a clearer framework ...

With the win fleshed out, AZ and Amgen are now eyeing regulatory filings to carve out a potential third indication for ...

Veradermics is keeping pace in an already high-octane year.  | Topline results show the biotech's lead asset, VDPHL01, ...

Next-gen manufacturer Antheia is teaming up with the U.S. Department of War to build out its infrastructure and onshore the U.S. drug supply chain.  | The Department of War is allotting a conditional ...

Cosette Pharmaceuticals has achieved a corporate milestone, securing an FDA approval for a legacy Daiichi Sankyo drug in its ...

AbbVie has formed a multiyear deal with the McLaren Formula 1 team, signing up to raise awareness of immune-mediated diseases ...

Eli Lilly is betting on a pediatric expansion to give it’s IL-23p19 inhibitor Omvoh an edge in the fiercely competitive ...

Amid tensions over government healthcare cost-cutting policies, Roche has slammed the brakes on new investments in Germany, joining an expanding group of drugmakers pulling back from the European ...